Celaid Therapeutics Inc. has completed the second close of its Series B financing round, raising JPY 400 million, approximately USD 2.6 million, through a third-party allocation of new shares. The round welcomed Shionogi & Co., Ltd. and Teikoku Ventures, Inc. as new investors, and Celaid also passed the second stage-gate review of AMED's Strengthening Program for Pharmaceutical Startup Ecosystem, securing selection for Stage 3 funding. With this financing and AMED support, Celaid's cumulative funding raised to date, including grants, now totals approximately JPY 3.42 billion, or approximately USD 22.1 million. Proceeds will be allocated primarily to manufacturing, safety assessment, clinical development, and regulatory activities supporting the IND application for CLD-001, a novel ex vivo-expanded hematopoietic stem cell therapy for severe pediatric non-malignant diseases, and the initiation of clinical trials in the United States. The company said the new participation from pharmaceutical companies represents significant momentum as it advances U.S. development of CLD-001, which has already completed a Pre-IND Meeting with the U.S. Food and Drug Administration.
Shionogi & Co., Ltd.Shionogi participated as a new investor in Celaid Therapeutics' JPY 400 million Series B second close
Shanghai Henlius Biotech Inc
Commercial Metals Company
